12/4
08:15 am
hrtx
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Medium
Report
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
11/6
05:10 pm
hrtx
Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear [Seeking Alpha]
Neutral
Report
Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear [Seeking Alpha]
11/4
08:12 pm
hrtx
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/4
08:00 am
hrtx
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Medium
Report
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
10/29
05:58 pm
hrtx
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Low
Report
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
10/21
04:20 pm
hrtx
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Medium
Report
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
10/9
07:15 am
hrtx
Heron Therapeutics (NASDAQ:HRTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Heron Therapeutics (NASDAQ:HRTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
9/9
05:30 pm
hrtx
Heron Therapeutics files $125M mixed securities shelf [Seeking Alpha]
Medium
Report
Heron Therapeutics files $125M mixed securities shelf [Seeking Alpha]